PURPOSE: To determine if the tumor-targeted cytotoxin interleukin 13 bound to Pseudomonas exotoxin (IL13-PE) could be delivered to the brainstem safely at therapeutic doses while monitoring its distribution in real-time using a surrogate magnetic resonance imaging tracer, we used convection-enhanced delivery to perfuse rat and primate brainstems with IL13-PE and gadolinium-bound albumin (Gd-albumin). EXPERIMENTAL DESIGN: Thirty rats underwent convective brainstem perfusion of IL13-PE (0.25, 0.5, or 10 microg/mL) or vehicle. Twelve primates underwent convective brainstem perfusion of either IL13-PE (0.25, 0.5, or 10 microg/mL; n = 8), co-infusion of 125I-IL13-PE and Gd-albumin (n = 2), or co-infusion of IL13-PE (0.5 microg/mL) and Gd-albumin (n = 2). The animals were permitted to survive for up to 28 days before sacrifice and histologic assessment. RESULTS: Rats showed no evidence of toxicity at all doses. Primates showed no toxicity at 0.25 or 0.5 microg/mL but showed clinical and histologic toxicity at 10 microg/mL. Quantitative autoradiography confirmed that Gd-albumin precisely tracked IL13-PE anatomic distribution and accurately showed the volume of distribution. CONCLUSIONS: IL13-PE can be delivered safely and effectively to the primate brainstem at therapeutic concentrations and over clinically relevant volumes using convection-enhanced delivery. Moreover, the distribution of IL13-PE can be accurately tracked by co-infusion of Gd-albumin using real-time magnetic resonance imaging.
PURPOSE: To determine if the tumor-targeted cytotoxin interleukin 13 bound to Pseudomonas exotoxin (IL13-PE) could be delivered to the brainstem safely at therapeutic doses while monitoring its distribution in real-time using a surrogate magnetic resonance imaging tracer, we used convection-enhanced delivery to perfuse rat and primate brainstems with IL13-PE and gadolinium-bound albumin (Gd-albumin). EXPERIMENTAL DESIGN: Thirty rats underwent convective brainstem perfusion of IL13-PE (0.25, 0.5, or 10 microg/mL) or vehicle. Twelve primates underwent convective brainstem perfusion of either IL13-PE (0.25, 0.5, or 10 microg/mL; n = 8), co-infusion of 125I-IL13-PE and Gd-albumin (n = 2), or co-infusion of IL13-PE (0.5 microg/mL) and Gd-albumin (n = 2). The animals were permitted to survive for up to 28 days before sacrifice and histologic assessment. RESULTS: Rats showed no evidence of toxicity at all doses. Primates showed no toxicity at 0.25 or 0.5 microg/mL but showed clinical and histologic toxicity at 10 microg/mL. Quantitative autoradiography confirmed that Gd-albumin precisely tracked IL13-PE anatomic distribution and accurately showed the volume of distribution. CONCLUSIONS: IL13-PE can be delivered safely and effectively to the primate brainstem at therapeutic concentrations and over clinically relevant volumes using convection-enhanced delivery. Moreover, the distribution of IL13-PE can be accurately tracked by co-infusion of Gd-albumin using real-time magnetic resonance imaging.
Authors: Gautam U Mehta; John D Heiss; John K Park; Ashok R Asthagiri; Kareem A Zaghloul; Russell R Lonser Journal: World Neurosurg Date: 2010-07 Impact factor: 2.104
Authors: Jung Hwan Kim; Garrett W Astary; Svetlana Kantorovich; Thomas H Mareci; Paul R Carney; Malisa Sarntinoranont Journal: Ann Biomed Eng Date: 2012-04-25 Impact factor: 3.934
Authors: Adam M Sonabend; R Morgan Stuart; Jonathan Yun; Ted Yanagihara; Hamed Mohajed; Steven Dashnaw; Samuel S Bruce; Truman Brown; Alex Romanov; Manu Sebastian; Fernando Arias-Mendoza; Emilia Bagiella; Peter Canoll; Jeffrey N Bruce Journal: Neuro Oncol Date: 2011-07-12 Impact factor: 12.300
Authors: Dale Ding; Charles W Kanaly; Thomas J Cummings; James E Herndon; Raghu Raghavan; John H Sampson Journal: Neurol Res Date: 2009-12-21 Impact factor: 2.448
Authors: Neal Luther; Zhiping Zhou; Pat Zanzonico; Nai-Kong Cheung; John Humm; Mark A Edgar; Mark M Souweidane Journal: Neuro Oncol Date: 2014-02-12 Impact factor: 12.300
Authors: Richard C E Anderson; Benjamin Kennedy; Candix L Yanes; James Garvin; Michael Needle; Peter Canoll; Neil A Feldstein; Jeffrey N Bruce Journal: J Neurosurg Pediatr Date: 2012-12-14 Impact factor: 2.375